Spero Therapeutics Inc (SPRO)

Dec 28, 2024

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat

Dec 28, 2024

Dec 23, 2024

Spero Therapeutics (NASDAQ:SPRO) Cut to In-Line at Evercore ISI - Defense World

Dec 23, 2024

Dec 20, 2024

Evercore ISI Group Downgrades Spero Therapeutics (SPRO) - MSN

Dec 20, 2024

Dec 20, 2024

Spero Therapeutics (NASDAQ:SPRO) Lowered to In-Line Rating by Evercore ISI - MarketBeat

Dec 20, 2024

Dec 20, 2024

What 4 Analyst Ratings Have To Say About Spero Therapeutics - Benzinga

Dec 20, 2024

Dec 16, 2024

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Dec 16, 2024

Dec 13, 2024

Spero Therapeutics (NASDAQ:SPRO) Stock Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat

Dec 13, 2024

Dec 04, 2024

Research Analysts Set Expectations for SPRO FY2024 Earnings - MarketBeat

Dec 04, 2024

Dec 04, 2024

Spero Therapeutics Q3 2024 Earnings Preview - MSN

Dec 04, 2024

Dec 02, 2024

Wainwright reiterates Buy rating on Spero Therapeutics with PIVOT-PO enrolment on track - Investing.com Canada

Dec 02, 2024

Nov 26, 2024

Carbapenem Market Size, Trends, Growth, Opportunities - openPR

Nov 26, 2024

Nov 20, 2024

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024

Nov 20, 2024

TD Cowen Reaffirms “Hold” Rating for Spero Therapeutics (NASDAQ:SPRO) - Defense World

Nov 20, 2024

Nov 19, 2024

Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

Nov 19, 2024

Nov 18, 2024

Spero Therapeutics' (SPRO) "Hold" Rating Reiterated at TD Cowen - MarketBeat

Nov 18, 2024

Nov 17, 2024

Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024

Nov 16, 2024

Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 16, 2024

Nov 15, 2024

Spero Therapeutics (NASDAQ:SPRO) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat

Nov 15, 2024

Nov 15, 2024

Spero Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 15, 2024

Nov 14, 2024

Spero Therapeutics Inc. (SPRO) Quarterly 10-Q Report - Quartzy

Nov 14, 2024

Nov 14, 2024

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update - GlobeNewswire

Nov 14, 2024

Nov 14, 2024

Spero Therapeutics Reports Wider Q3 Loss, Revenue Falls 47% Amid Restructuring | SPRO Stock News - StockTitan

Nov 14, 2024

Nov 13, 2024

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnin - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings - Yahoo Finance

Nov 13, 2024

Nov 13, 2024

Spero Therapeutics (SPRO) Scheduled to Post Earnings on Thursday - Defense World

Nov 13, 2024

Nov 08, 2024

Spero Therapeutics (SPRO) to Release Earnings on Thursday - MarketBeat

Nov 08, 2024

Nov 08, 2024

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 - The Manila Times

Nov 08, 2024

Nov 07, 2024

Spero Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire

Nov 07, 2024

Nov 06, 2024

HC Wainwright Expects Higher Earnings for Spero Therapeutics - MarketBeat

Nov 06, 2024

Nov 05, 2024

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights

Nov 05, 2024

Nov 04, 2024

Spero shares hold Buy rating with target lowered on SPR720 Phase 2a results - Investing.com UK

Nov 04, 2024

Nov 04, 2024

HC Wainwright Cuts Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00 - MarketBeat

Nov 04, 2024

Nov 02, 2024

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding - Simply Wall St

Nov 02, 2024

Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024

Oct 31, 2024

Cambridge biotech pulls plug on lung disease drug, cuts 39% of workforce - The Business Journals

Oct 31, 2024

Oct 31, 2024

Spero Therapeutics to lay off 39% of employees - PharmaLive

Oct 31, 2024

Oct 30, 2024

Spero Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com South Africa

Oct 30, 2024

Oct 30, 2024

Spero Therapeutics to Lay Off 39% of Employees - BioSpace

Oct 30, 2024

Oct 30, 2024

Spero Therapeutics stock hits 52-week low at $1.03 - Investing.com

Oct 30, 2024

Oct 30, 2024

Spero’s stock slides after antibiotic flops in Phase II trial - Yahoo Finance

Oct 30, 2024

Oct 29, 2024

Spero Therapeutics reports setback in SPR720 study By Investing.com - Investing.com South Africa

Oct 29, 2024

Oct 29, 2024

Biopharma Co. Escapes Investor Suit Over Drug Approval Lies - Law360

Oct 29, 2024

Oct 29, 2024

Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program - MarketWatch

Oct 29, 2024

Oct 29, 2024

Spero to cut 39% of workforce on failed study, stock plunges 20% (NASDAQ:SPRO) - Seeking Alpha

Oct 29, 2024

Oct 29, 2024

Spero Therapeutics reports setback in SPR720 study - Investing.com India

Oct 29, 2024

Oct 29, 2024

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - GlobeNewswire

Oct 29, 2024

Oct 29, 2024

Spero Therapeutics Dodges Investor Suit Over FDA Approval (1) - Bloomberg Law

Oct 29, 2024

Oct 27, 2024

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance

Oct 27, 2024